Related references
Note: Only part of the references are listed.The Immune Revolution: A Case for Priming, Not Checkpoint
Robert H. Vonderheide
CANCER CELL (2018)
The revival of CpG oligonucleotide-based cancer immunotherapies
Tomasz Adamus et al.
Wspolczesna Onkologia-Contemporary Oncology (2018)
Warming Cold Melanoma with TLR9 Agonists
Alissa Poh
CANCER DISCOVERY (2018)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Matthew J. Frank et al.
CANCER DISCOVERY (2018)
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Antoni Ribas et al.
CANCER DISCOVERY (2018)
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
David A. Knorr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Gregory L. Beatty et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
Rony Dahan et al.
CANCER CELL (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
Antitumour actions of interferons: implications for cancer therapy
Belinda S. Parker et al.
NATURE REVIEWS CANCER (2016)
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Sima Rahimian et al.
BIOMATERIALS (2015)
Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
Ann L. White et al.
CANCER CELL (2015)
The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
Sara M. Mangsbo et al.
CLINICAL CANCER RESEARCH (2015)
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
Linda C. Sandin et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells
Masayasu Naito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
FcγRI™I™B controls the potency of agonistic anti-TNFR mAbs
Ann L. White et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
C. Manegold et al.
ANNALS OF ONCOLOGY (2012)
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
Clive S. Zent et al.
LEUKEMIA & LYMPHOMA (2012)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2011)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
Vera Hirsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
Fubin Li et al.
SCIENCE (2011)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Youn H. Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Roch Houot et al.
BLOOD (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Antigen-presentation properties of plasmacytoid dendritic cells
Jose A. Villadangos et al.
IMMUNITY (2008)
Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma
Maja A. Hofmann et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
A. M. Krieg
ONCOGENE (2008)
Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Jiali Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Development of TLR9 agonists for cancer therapy
Arthur M. Krieg
JOURNAL OF CLINICAL INVESTIGATION (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Clinical translation of angiogenesis inhibitors
R Kerbel et al.
NATURE REVIEWS CANCER (2002)
Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model
K Heckelsmiller et al.
JOURNAL OF IMMUNOLOGY (2002)
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody
AP Vicari et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity
GJD van Mierlo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells
JG Turner et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
